Biogen's highly anticipated anti-LINGO data fall flat
This article was originally published in Scrip
After several months of questions about when Biogen Idec would reveal its first proof-of-concept data for the anti-LINGO development program, the company reported results from a Phase II clinical trial in the treatment of acute optic neuritis (AON) that gave no clear answers about the treatment's effects in multiple sclerosis (MS).
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.